Kexing Biopharm Co., Ltd. (SHA:688136)

China · Delayed Price · Currency is CNY

20.77

-0.40 (-1.89%)

Sep 2, 2026, 2:55 PM CST

Kexing Biopharm Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,441	1,534	1,407	1,259	1,316	1,285
Revenue Growth	6.92%	9.03%	11.75%	-4.32%	2.39%	5.32%
Gross Profit	853.91	969.71	962.73	888.72	991.21	1,020
Operating Income	-36.87	88.08	98.52	-240.71	-125.34	42.21
Net Income	209.17	155.57	31.48	-190.29	-90.3	96.46
Earnings Per Share	1.06	0.79	0.16	-0.96	-0.45	0.49
EPS Growth	109.21%	393.75%	-	-	-	-47.31%

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
China	1,168
Export	366.29
Total	1,534

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	609.87	650.43	554.56	568.8	785.38	877.62
Total Debt	1,459	1,397	1,221	1,116	1,039	601.27
Net Cash (Debt)	-849.34	-746.33	-666.22	-547.26	-253.16	276.35
Net Cash Growth	-	-	-	-	-	-64.88%
Net Cash Per Share	-4.30	-3.79	-3.39	-2.76	-1.26	1.40

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	81.48	86.03	106.67	-87.14	-85.89	94.01
Capital Expenditures	-90.38	-83.63	-93.99	-191.2	-399.17	-371.98
Free Cash Flow	-8.91	2.4	12.68	-278.34	-485.06	-277.97
Free Cash Flow Growth	-	-81.05%	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	59.27%	63.21%	68.43%	70.59%	75.33%	79.36%
Operating Margin	-2.56%	5.74%	7.00%	-19.12%	-9.53%	3.28%
Pretax Margin	15.87%	10.80%	4.04%	-20.66%	-10.57%	7.44%
Profit Margin	14.52%	10.14%	2.24%	-15.11%	-6.86%	7.51%
FCF Margin	-0.62%	0.16%	0.90%	-22.11%	-36.86%	-21.63%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 2, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	0.250	0.250	0.080	-	-	0.100
Dividend Per Share Growth	212.50%	212.50%	-	-	-	25.00%
Dividend Yield	1.22%	0.80%	0.37%	-	-	0.36%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 2, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	20.01	40.33	137.32	-	-	58.23
Forward PE	34.15	38.04	41.58	-	-	-
P/FCF Ratio	-	2611.79	340.98	-	-	-
PS Ratio	2.91	4.09	3.07	3.20	3.24	4.37